Nucleocapsid protein binding DNA aptamers for detection of SARS-COV-2.

Autor:	Neff CP; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., Cikara M; Precision Medicine Architects, LLC, PO Box 148, Wellington, CO 80549, United States., Geiss BJ; Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523, USA., Thomas Caltagirone G; Aptagen, LLC, 250 North Main Street, Jacobus, PA 17407, USA., Liao A; Aptagen, LLC, 250 North Main Street, Jacobus, PA 17407, USA., Atif SM; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., Macdonald B; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., Schaden R; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Jazyk:	angličtina
Zdroj:	Current research in biotechnology [Curr Res Biotechnol] 2023; Vol. 5, pp. 100132. Date of Electronic Publication: 2023 May 27.
DOI:	10.1016/j.crbiot.2023.100132
Abstrakt:	The severe acute respiratory syndrome coronavirus (SARS-CoV-2) has infected millions of individuals and continues to be a major health concern worldwide. While reverse transcription-polymerase chain reaction remains a reliable method for detecting infections, limitations of this technology, particularly cost and the requirement of a dedicated laboratory, prevent rapid viral monitoring. Antigen tests filled this need to some extent but with limitations including sensitivity and specificity, particularly against emerging variants of concern. Here, we developed aptamers against the SARS-CoV-2 Nucleocapsid protein to complement or replace antibodies in antigen detection assays. As detection reagents in ELISA-like assays, our DNA aptamers were able to detect as low as 150 pg/mL of the protein and under 150 k copies of inactivated SARS-CoV-2 Wuhan Alpha strain in viral transport medium with little cross-reactivity to other human coronaviruses (HCoVs). Further, our aptamers were reselected against the SARS-CoV-2 Omicron variant of concern, and we found two sequences that had a more than two-fold increase in signal compared to our original aptamers when used as detection reagents against protein from the Omicron strain. These findings illustrate the use of aptamers as promising alternative detection reagents that may translate for use in current tests and our findings validate the method for the reselection of aptamers against emerging viral strains. Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [G. Thomas Caltagirone and Albert Liao reports a relationship with Aptagen that includes: employment.]. (© 2023 The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu